Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Study Phase : Phase I
Recipient : Bio-Thera Solutions
Deal Size : Undisclosed
Deal Type : Agreement
Bio-Thera and SteinCares Expand Partnership to Commercialize Biosimilars
Details : Bio-Thera will be responsible for development and supply of a proposed biosimilar of dupilumab, while SteinCares will lead the registration and commercialization across Latin America.
Product Name : BAT2406
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
June 25, 2025
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Bio-Thera Solutions
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lupin Inks Licensing Deal to Supply Biosimilar Ranibizumab in Latin America
Details : SteinCares will handle all regulatory filings, registrations and commercialisation of LUBT010 (ranibizumab) in Latin America, while Lupin will be responsible for manufacturing the same.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
May 26, 2025
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : CStone Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
CStone Partners with SteinCares to Market Sugemalimab in Latin America
Details : Under this agreement, SteinCares will gain the commercialization rights for Cejemly (sugemalimab) in 10 LATAM countries.
Product Name : Cejemly
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
January 26, 2025
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : CStone Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement